SHL Medical and Lifecore Biomedical Collaborate to Enhance Drug Delivery Systems

Lifecore, as a fully integrated contract development and manufacturing organization (“CDMO”), offers highly differentiated capabilities in the development, filling and processing of complex sterile injectable pharmaceutical products into syringes and ampoules.

Through this partnership, Lifecore becomes a member of SHL’s recently announced Alliance Management program, an initiative designed to further strengthen SHL’s vertically integrated business model by facilitating customer collaboration with other key players in the drug delivery ecosystem.

Under the terms of their agreement, SHL and Lifecore will share knowledge and experience in their respective areas of expertise. This enables both companies to provide their customers with the best possible advice on CDMO services and offer first-class options for the development of drug delivery systems.

As a market leader and pioneer in the field of autoinjectors, SHL provides drug delivery solutions and has vertically integrated capabilities for the development, manufacturing and final assembly of its autoinjector products. By partnering with Lifecore, SHL will be able to recommend a trusted CDMO known for its proven expertise and robust quality systems in aseptic pharmaceutical manufacturing and primary container filling. This creates a comprehensive support system for all phases of the development and commercial life cycle of autoinjectors.

“As a true partner to the pharmaceutical and biotech industries, we believe in providing comprehensive, end-to-end solutions that improve patients’ quality of life and enable them to be independent,” said Kimberlee Steele, Managing Director of SHL Pharma, the final assembly business unit, Labeling and packaging from SHL Medical in Florida. “We are pleased to partner with Lifecore to provide high quality CDMO services that perfectly complement our own high-touch approach to customer support.”

Darren Hieber, Senior Vice President of Corporate Development and Partnerships at Lifecore, commented: “We are constantly adapting to keep pace with evolving healthcare treatments and technologies, and our extensive expertise in filling and processing syringes and ampoules is a natural fit SHL’s products. Through our partnership with SHL, we can provide a broader offering to our CDMO customers, enabling them to offer the benefits and convenience of innovative drug delivery systems to their patients worldwide. We are pleased to partner with an industry leader with its unique, practical and “Offers a high-quality product portfolio that offers patient-oriented solutions.”

About SHL Medical As a global leader in advanced drug delivery systems, SHL Medical is the preferred partner of many major pharmaceutical and biotech companies. The company’s goal is “Enabling Patients’ Independence”. Driven by this, SHL Medical offers patient-oriented solutions for the design, development and manufacture of auto-injectors, pen injectors and innovative specialty delivery systems for large-volume and high-viscosity formulations. The company also offers final assembly, labeling and packaging solutions for its drug delivery systems.

In response to the increasing trend of home therapy, SHL Medical has increased its digital healthcare development work to further improve the drug delivery ecosystem.

With locations in Switzerland, Taiwan, Sweden and the USA, SHL Medical’s global team of experts works seamlessly as one team, leveraging its extensive in-house manufacturing capabilities. The company’s solutions provide customization and optimization for each project, while proactively incorporating sustainability-focused measures into designs and processes to contribute to a cleaner environment. For more information, see .

About Lifecore Biomedical Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (“CDMO”) that provides highly differentiated capabilities in the development, filling and processing of complex sterile injectable pharmaceutical products into syringes and vials. As a leading manufacturer of high quality injectable hyaluronic acid, Lifecore has more than 40 years of experience. Lifecore partners with global and emerging biopharmaceutical and biotechnology companies across diverse therapeutic categories, helping them bring their innovations to market. For more information about the Company, please visit Lifecore’s website at .

Important Notes Regarding Forward-Looking Statements

This press release contains forward-looking statements about future events and results, including the expected relationship between SHL and Lifecore. These statements are subject to the Safe Harbor Act, created as part of the Private Securities Litigation Reform Act of 1995, and other safe harbor laws created as part of the Securities Act of 1933 and the Securities Exchange Act of 1934. Words like “predict”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “could”, “will”, “should”, “could have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors as, among others, the nature and requirements of the relationship between SHL and Lifecore, the ability to achieve market acceptance of Lifecore’s new products, and legal regulations that influence the respective business of the company. For further information about factors that could cause actual results to differ materially from those described in the forward-looking statements, see Lifecore’s filings with the Securities and Exchange Commission, including the risk factors discussed in our most recent quarterly report on Form 10-Q and included in the Annual Report on Form 10-K/A. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, neither company undertakes any obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Press contact:

MedienkontaktCarl GillbladCommunications and Marketing Operationsmailto:[email protected]+41 41 368 00 00

Alliance Management-KontaktAlina SmotrovaCorporate Developmentmailto:[email protected]+41 41 368 00 00

Lifecore Investor RelationsJeff Sonnekmailto:[email protected](646) 277-1263

Additional material: SHL Medical